XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss $ (358) $ (4,445)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:    
Depreciation 665 758
Amortization of intangible assets 2,777 2,920
Amortization of deferred financing costs 140 140
Stock-based compensation expense 2,255 2,262
Deferred income taxes and other 86 1,040
Unrealized loss on equity securities - Note 14 1,581 (0)
Convertible Preferred Stock received in Biostage Settlement - Note 14 0 (3,900)
Gain on sale of product line (403) 0
Changes in operating assets and liabilities:    
Accounts receivable (68) 3,587
Inventories 398 (2,667)
Other assets (1,268) (250)
Accounts payable and accrued expenses (270) (435)
Deferred revenue 445 (611)
Other liabilities (616) (575)
Net cash provided by (used in) operating activities 5,364 (2,176)
Cash flows from investing activities:    
Additions to property, plant and equipment (741) (913)
Acquisition of intangible assets (108) 0
Proceeds from sale of product line 512 0
Net cash used in investing activities (337) (913)
Cash flows from financing activities:    
Borrowing from revolving line of credit 2,500 5,300
Repayment of revolving line of credit (5,450) (3,600)
Repayment of term debt (2,591) (1,686)
Proceeds from exercise of stock options and employee stock purchase plan 724 282
Taxes paid related to net share settlement of equity awards (451) (780)
Net cash used in financing activities (5,268) (484)
Effect of exchange rate changes on cash 57 11
Decrease in cash and cash equivalents (184) (3,562)
Cash and cash equivalents at beginning of period 4,508 7,821
Cash and cash equivalents at end of period 4,324 4,259
Supplemental disclosures of cash flow information:    
Cash paid for interest 2,148 845
Cash paid for income taxes, net of refunds $ 115 $ 352